What are the consequences of discontinuing canafenib/encofenib?

Encorafenib is a BRAF inhibitor targeted drug that is widely used to treat malignant tumors with BRAF V600E mutations, especially in the fields of melanoma and colorectal cancer. It has shown strong efficacy. Because its mechanism of action is to continuously inhibit the mutant BRAF signaling pathway, thereby blocking the growth and proliferation of tumor cells, treatment with canafenib requires a high degree of continuity. If canafenib is stopped hastily without medical guidance, it is likely to bring about the risk of rapid disease progression, and even induce a rebound in tumor load, affecting overall survival. Some patients will experience a rebound in tumor indicators or an increase in imaging lesions within a short period of time after stopping the drug. This "rebound effect" is closely related to the reactivation of cellular pathways after drug intervention is interrupted.

In addition, the metabolic characteristics and half-life of canafenib also determine that once its efficacy is terminated, the tumor suppressor signal in the body will rapidly weaken. Especially in patients treated with MEK inhibitors such as binimetinib, stopping the use of canafenib alone may disrupt the entire treatment balance, cause side effects or reduce efficacy. More importantly, drug discontinuation not only affects disease control, but may also cause patients to lose sensitivity to targeted therapy again. The effect of restarting therapy in the future may not be as significant as when it was first administered.

Therefore, for patients receiving canafenib treatment, whether to discontinue treatment must be based on disease assessment, review of gene mutation status, and clear recommendations from doctors. Some patients may be forced to suspend medication due to adverse reactions such as skin rash, elevated liver enzymes, etc. However, in such cases, the dose should be gradually adjusted or the regimen changed under the supervision of a physician rather than complete discontinuation of medication. Especially patients whose condition is stable should not interrupt treatment without permission. In short, as a targeted drug, canafenib’s treatment continuity is crucial to disease control. Stopping the drug hastily may lead to irreversible treatment consequences, so it must be handled with caution.

Reference materials:https://www.braftovi.com/